Knowledge Library
Discovery and preclinical evaluations of GST-HG131, a novel HBV antigen inhibitor for the treatment of chronic hepatitis B infection
Chronic HBV infection (CHB) is a major contributor to liver-related deaths worldwide. The ultimate endpoint of CHB treatment is sustained HBV surface antigen (HBsAg) loss. Here, we report the design of a series of HBV surface antigen inhibitors which promotes reduction of HBV antigens in vitro and in vivo. https://pubmed.ncbi.nlm.nih.gov/36089112/
Alpha‐kinase 1 (ALPK1) agonist DF‐006 demonstrates potent efficacy in mouse and primary human hepatocyte models of hepatitis B
WuXi AppTec scientists recently contributed to a research study published in the journal Hepatology, characterizing the efficacy of prodrug DF-006 for treating chronic hepatitis B infection. DF-006 is an orally active agonist of alpha‐kinase 1, a pattern recognition receptor involved in the stimulation of innate immunity. The authors show that DF‐006 is efficacious in hepatitis …Read More >
Large-scale synthesis of a Notum inhibitor employing a modified Sakai reaction as the key step
WuXi AppTec scientists recently contributed to a research article in the Royal Society of Chemistry describing the large-scale synthesis of a potent and selective inhibitor of Notum carboxylesterase (an enzyme that suppresses Wnt signaling pathways). By employing a modified Sakai reaction as the key step, a one-pot synthesis of this Notum inhibitor was developed, enabling …Read More >
WuXi AppTec Oligonucleotide Biology Platform
WuXi Biology oligonucleotide capabilities Sequence design Knockdown effect incell lines and primary cells (transfection d f uptake) Splicing analysis Functional assays Other assays: Tm determination Cytotoxicity lmmunotoxicity Off-target effect “Humanized” mouse models Transgenic, HDI and AAV mouse models NHP models Short and longterm KD efficacy/ harmacology readouts GalNAc-ASGPR delivery system SPR screening Customized assays for …Read More >
How Does It Work? | RNAi
As part of our dedication to providing an #openaccess platform, so our entire ecosystem can come together to share #science & #collaborate to better the lives of all #patientsfirst. We’ve created MoA animations in our new series exploring biotech topics on a molecular level. Protein malfunctions cause many diseases, but a new approach is emerging …Read More >
WuXi AppTec Discovery Services
Delivering comprehensive end-to-end solutions for creating, identifying, and supporting preclinical candidates, from discovery to development, with our integrated chemistry and biology research platform. Integrated Chemistry and Biology Research Platform | From Discovery to Candidate Selection and Beyond
NASH Animal Models and their Clinical Relevance – Quantitative Histopathology of Hepatic Fibrosis
Novel Strategies to Accelerate Discovery of Translatable Therapeutic Targets
Quantitative Histopathology of Fibrosis in an Animal Model of NASH
The hepatic fibrosis has been the most challenging aspect in the animal models for nonalcoholic steatohepatitis (NASH). Although it could induced by nutritional (high-fat died with high cholesterol, methionine and choline deficient diet, etc), chemical (carbon tetrachloride, thioacetamide, α-naphthylisothiocyanate etc.), and surgical (bile duct ligation) means, the clinical relevance of the resulting fibrosis remains an …Read More >